Metastatic Renal Cell Carcinoma Recruiting Phase 1 / 2 Trials for Ibrutinib (DB09053)

Also known as: Metastatic Renal cell carcinoma

IndicationStatusPhase
DBCOND0030098 (Metastatic Renal Cell Carcinoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02599324A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary TumorsTreatment